[Treatment of acute leukemia with 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine hydrochloride (cyclocytidine) (author's transl)]. 1973

T Masaoka, and Y Hasegawa, and N Tatsumi, and H Nakamura, and J Yoshitake

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

T Masaoka, and Y Hasegawa, and N Tatsumi, and H Nakamura, and J Yoshitake
January 1978, The Tohoku journal of experimental medicine,
T Masaoka, and Y Hasegawa, and N Tatsumi, and H Nakamura, and J Yoshitake
February 1977, Antimicrobial agents and chemotherapy,
T Masaoka, and Y Hasegawa, and N Tatsumi, and H Nakamura, and J Yoshitake
March 1975, Journal of pharmaceutical sciences,
T Masaoka, and Y Hasegawa, and N Tatsumi, and H Nakamura, and J Yoshitake
January 1972, The Journal of organic chemistry,
T Masaoka, and Y Hasegawa, and N Tatsumi, and H Nakamura, and J Yoshitake
May 1974, Journal of medicinal chemistry,
T Masaoka, and Y Hasegawa, and N Tatsumi, and H Nakamura, and J Yoshitake
July 1981, [Rinsho ketsueki] The Japanese journal of clinical hematology,
T Masaoka, and Y Hasegawa, and N Tatsumi, and H Nakamura, and J Yoshitake
June 1973, Cancer research,
T Masaoka, and Y Hasegawa, and N Tatsumi, and H Nakamura, and J Yoshitake
October 1974, Biochemical pharmacology,
T Masaoka, and Y Hasegawa, and N Tatsumi, and H Nakamura, and J Yoshitake
May 1974, Journal of the National Cancer Institute,
Copied contents to your clipboard!